{"entity":{"id":"nordic-lymphoma-group","kind":"company","name":"Nordic Lymphoma Group","aka":["NLG"],"tldr":"The Danish, Finnish, Norwegian, Swedish and Icelandic lymphoma trials network, best known for the Nordic mantle cell lymphoma regimen.","summary":"The Nordic Lymphoma Group coordinates investigator-initiated lymphoma trials and registries across the Nordic countries, which share population registries that make long-term follow-up unusually complete. Its MCL2 and MCL3 trials established the Nordic regimen of intensified cytarabine-containing induction with rituximab and autologous transplant for younger patients with mantle cell lymphoma. NLG working groups cover aggressive, indolent, T-cell and Hodgkin lymphomas and collaborate with HOVON, the German groups, LYSA and IELSG. The group rotates its chair among the member countries.","asOf":"2026-09-09","links":[{"label":"Nordic Lymphoma Group","url":"https://www.nordic-lymphoma.org"}],"tags":["cooperative-group"],"related":[],"cancers":["dlbcl","hodgkin-lymphoma","cll"],"sections":[],"technologies":["monoclonal-antibody","cytotoxic-chemotherapy"],"targets":[],"drugs":[],"companies":["hovon","ielsg"],"institutions":["karolinska"],"pathways":[],"terms":[],"trials":[],"people":["sirpa-leppa"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Nordic MCL2/MCL3 regimen","T-cell lymphoma trials","Registry-based outcome studies","Hodgkin lymphoma collaborations"],"provenance":{"editedBy":"OnCo cooperative groups migration (row 251: institution consortium records moved to cooperative-group companies)","editedOn":"2026-09-25"},"hq":"Stockholm","country":"SE","companyType":"cooperative-group","website":"https://www.nordic-lymphoma.org","investors":[],"funding":[]},"route":"/companies/nordic-lymphoma-group/","neighbours":{"cancer":[{"id":"cll","kind":"cancer","name":"Chronic lymphocytic leukaemia","route":"/cancers/cll/"},{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"},{"id":"hodgkin-lymphoma","kind":"cancer","name":"Hodgkin lymphoma","route":"/cancers/hodgkin-lymphoma/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"}],"company":[{"id":"hovon","kind":"company","name":"HOVON","route":"/companies/hovon/"},{"id":"ielsg","kind":"company","name":"International Extranodal Lymphoma Study Group","route":"/companies/ielsg/"}],"institution":[{"id":"karolinska","kind":"institution","name":"Karolinska University Hospital","route":"/institutions/karolinska/"}],"person":[{"id":"mansoor-raza-mirza","kind":"person","name":"Mansoor Raza Mirza","route":"/people/mansoor-raza-mirza/"},{"id":"sirpa-leppa","kind":"person","name":"Sirpa Leppä","route":"/people/sirpa-leppa/"}]}}